期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

噻唑烷二酮类药物对2型糖尿病患者骨代谢的影响及其机制 被引量：2

The effects and their mechanisms of thiazolidinediones on bone metabolism in the patients with type 2 diabetes
原文传递
导出
摘要 TZDs类药物是近年来常用的一类口服降糖药,其可能会对糖尿病患者的骨代谢产生不良影响,使骨密度下降,甚至导致骨折风险增加。本文就TZDs类药物对糖尿病患者骨代谢的影响及其可能机制进行综述。 Thiazolidinediones （TZDs） , selective agonists of peroxisome proliferator-activated receptor gamma, are oral anti-diabetic drugs, Several large-scale clinical trials have reported that TZDs may contribute to decreased bone mineral density and increased risk of fracture. In this article, the effects and mechanisms of thiazolidinediones on bone metabolism in the patients with type 2 diabetes are reviewed in details.
作者 侯文芳 肖文华 洪天配
机构地区 北京大学第三医院内分泌科
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2013年第7期666-668,共3页 Chinese Journal of Diabetes
关键词 噻唑烷二酮类药物 糖尿病 2型 骨代谢 Thiazolidinediones Diabetes mellitus, type 21 Bone metabolism
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献18

  • 1Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidin- edione use and bone loss in older diabetic adults. J Clin Endocrinol Metab, 2006, 91:3349-3354. 被引量：1
  • 2Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care, 2007, 30:1574-1576. 被引量：1
  • 3Grey A, Bolland M, Gamble G, et al. The peroxisome prolif- erator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmeno- pausal women: A randomized, controlled trial. J Clin Endocrinol Metab, 2007, 92:1305-1310. 被引量：1
  • 4Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes.. An analysis from a diabetes out- come progression trial (ADOPT). Diabetes Care, 2008, 31:845-851. 被引量：1
  • 5Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet, 2009, 373:2125-35. 被引量：1
  • 6Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-eontrolled trial. J Clin Endocrinol Metab, 2008, 93:1696-1701. 被引量：1
  • 7Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab, 2010, 95 : 134-142. 被引量：1
  • 8Kanazawa I, Yamaguchi T, Yano S, et al. Baseline atheroselerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int, 2010, 21:2013-2018. 被引量：1
  • 9Akune T, Ohba S, Kamekura S, et al. PPART insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest, 2004, 113:846-855. 被引量：1
  • 10Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone cau- ses bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology, 2005, 146:1226-1235. 被引量：1

二级参考文献21

  • 1Takahashi N,Udagawa N,Tanaka S,et al.Postmitotic osteoclast precursorsare mononuclear cells which express macrophageassociated phenotypes.Dev Biol,1994,163:212-221. 被引量：1
  • 2Berger J,Moiler DE.The mechanisms of action of PPARs.Annu Rev Med,2002,53:409-435. 被引量：1
  • 3Moore SG,Dawson KL.Red and yellow marrow in the femur:agerelated changes in mappearanee at MR imaging.Radiology,1990,175:219-223. 被引量：1
  • 4Kajkenova O,Lecka-Czemik B,Gubri I,et al.Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6,a murine model of defective osteoblastogenesis and low turnover osteopenia.J Bone Miuer Res,1997,12:1772-1779. 被引量：1
  • 5Mbalaviek G,Abu-Amer Y,Meng A,et al.Activation of peroxisome prollferator-activated receptor-gamma pathway inhibitsm osteoclast differentiation.J Biol Chem,2000,275:14388-14393. 被引量：1
  • 6Maunn AC,Chavassieux PM,Meunier PJ.Expression of PPAR gamma and beta/delta in human primary osteoblastic cells:influence of polyunsaturated fatty acids.Calcif Tissue Int,2005,76:385-392. 被引量：1
  • 7Kelly KA,Tanaka S,Baron R,et al.Murine bone marrows tremally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro.Endocrinology,1998,139:2092-2101. 被引量：1
  • 8Duong LT,Lakkakorpi P,Nakamura I,et al.Integrins and signaling in osteoclast function.Matrix Biol,2000,19:97-105. 被引量：1
  • 9Tetl A,Migliaccio S,Taranta A,et al.Mechanisms of osteoclastdysfunctionin human osteopetresis:abnormal osteoclastogenesis and lack of osteoelast-speelfie adhesion structures.J Bone Miner Res,1999,14:2107-2117. 被引量：1
  • 10Takeshi M,Fumlo A,Osamu O,et al.An adherent condition is required for formation of multinuelear osteoclasts in the presenee of macrophage colony-stlmulating factor and receptor activator of nuclear factor κB ligand.Blood,2000,96:4335-4343. 被引量：1

共引文献2

同被引文献44

  • 1Zhang P,Zhang X,Brown J,et al.Global healthcare expenditure on diabetes for 2010 and 2030[J].Diabetes Res Clin Pract,2010,87(3):293-301. 被引量：1
  • 2Janghorbani M,Van Dam RM,Willett WC,et al.Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture[J].Am J Epidemiol,2007,166(5):495-505. 被引量：1
  • 3Yamamoto M,Yamaguchi T,Yamauchi M,et al.Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications[J].J Bone Miner Res,2009,24(4):702-709. 被引量：1
  • 4Kanazawa I,Yamaguchi T,Yamamoto M,et al.Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus[J].J Bone Miner Metab,2010,28(5):554-560. 被引量：1
  • 5Ma X,Meng J,Jia M,et al.Exendin-4,a glucagon-like peptide-1receptor agonist,prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats[J].J Bone Miner Res,2013,28(7):1641-1652. 被引量：1
  • 6Ardawi MS,Akhbar DH,Alshaikh A,et al.Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes[J].Bone,2013,56(2):355-362. 被引量：1
  • 7Patsch JM,Li X,Baum T,et al.Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures[J].J Bone Miner Res,2013,28(8):1721-1728. 被引量：1
  • 8Melton LJ,Riggs BL,Leibson CL,et al.A bone structural basis for fracture risk in diabetes[J].J Clin Endocrinol Metab,2008,93(12):4804-4809. 被引量：1
  • 9Burghardt AJ,Issever AS,Schwartz AV,et al.High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2010,95(11):5045-5055. 被引量：1
  • 10Saito M,Marumo K.Collagen cross-links as a determinant of bone quality:a possible explanation of bone fragility in aging,osteoporosis,and diabetes mellitus[J].Osteoporos Int,2010,21(2):195-214. 被引量：1

引证文献2

二级引证文献9

中国糖尿病杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部